Retatrutide, a novel dual activator of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) target, is showing promising results in initial patient assessments . Current research https://social-medialink.com/story6413644/retatrutide-emerging-research-and-potential-therapeutic-uses